Brand Information

Updated On: 27-02-2024

Home

About Us

FAQs

Feedback

Disclaimer

Site Map

Home > Search > > CRESAR

CRESAR

Brand:
CRESAR

Manufacturer:
CIPLA

Manufacturer Details
CIPLA

Compositions:
Telmisartan 20mg/40mg/80mg tablets,

Strength	Rate	Packing Style
20mg	61.33	15s tablets
40mg	111.04	10s tablets
80mg	112.76	10s tablets

List of Related Indications:

Hypertension

List Of Drugs:

Telmisartan - Angiotensin II Antagonists- (FDC- List )- (May 2008)

Indication Type Description:

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Pregnancy and lactation

Drug Interaction:

Concurrent use increases digoxin concentration.

Increase risk of lithium toxicity Increases risk of hyperkalemia with K sparing diuretics

Heparin

Indication:

U.S,FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08

Drug name Indication Date of Approval

136. Telmisartan 40mg 22-05-08

+ Atorvastain (as calcium) 10mg tablets

For co-existing essential hypertension & hyperlipidemia

195. Telmisartan 15-09-08

+ Ramipril (40mg +2.5mg) Tablets

(Addl.stgth)

For the treatment of essential hypertension

U.S. FDA APPROVED DRUGS DURING 2006

130. Telmisartan 40mg + 30-08-2006

Amlodipine ( as Besylate) 5mg tablet For essential hypertension

Hypertension

Patent Expiry Date of drugs (Ref - IDMA Publication)

Chemical Category Manufacturer/ US Patent

Ingredient- Marketer Expiration Date

Telmistran Cardiovascular Boehringer 07-01-2014

Ingelheim

New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing

(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

1.Telmistran Anti-Hypertensive 25-11-2002

2.Telmistran 15-09-2008

+ Ramipril (40mg+ 2.5mg)

Tablets

Addl.Stgth

For the treatment of Essential Hypertension

3.Telmistran 40mg 22-05-2008

+ Atorvastatin as Calcium 10mg

Tablets

For Co-exiting Essential Hypertension & Hyperlipdemia

4.Telmistran 20mg 03-01-2013

+ Amlodipine 2.5mg

+ Hydrocholothiazide 6.25mg Tablets

Addl.Stgth

For the treament of Essential Hypertension

5.Telmistran 40/80mg 05-04-2010

+ Indapamide SR 1.5/1.5mg Tablet

For the treatment of Essential Hypertension

6.Telmistran 40mg 30-08-2006

+ Amlodipine Besylate 5mg tablet

For Essential Hypertension

7.Telmistran 80mg 31-03-2009

+ Amlodipine 5mg tablet

Addl.Higher Stgth

For essential Hypertension

8.Telmistran IP 80mg 14-05-2013

+ Hydrocholrothiazide IP 25mg

Uncoated Bilayered tablet

Addl.stgth

For the treatment of Hypertension as Secondary Line therapy

9.Telmistran Tablet 20/40/80mg 14-05-2010

Addl.Indcn

For the prevention of Cardiovascular Morbidity and Mortality in

Patients 55 years older, at Higher Risk of Cardiovascular

Disease

FIXED DOSE COMBINATIONS APPROVED BY DCG(I)

FROM JANUARY 1961 TILL NOVEMBER 2014

Name of Drug Indication Date of Approval

1.Each uncoated bilayered tablet contains: 14-05-2013

Telmisartan Ph.Eur IP 80mg +

Hydrochlorthiazide Ph.Eur 25mg

Addl.stgth

For the treatment of hypertension as second line therapy

2. Telmistran 40mg/80mg + 29-08-2003

Hydrochlorthiazide 12.5mg/12.5mg tablet

For treatment of hyertension as 2nd line therapy

3.Telmistran 80mg + 31-09-2009

Amlodipine 5mg tablet

Addl.Stgth

For essential hypertension

INFORMATION- UPDATE

TELMISTRAN - MODEST INCREASE IN CANCER RISK

Telmistran ( sold as TELPRES, TELPRES-H, XSTAN-H etc.) is associated with modestly increased risk of cancer, according to meta-analysis published by the Lancet Oncology. Researchers examining data from five randomized trials comprising nearly 62,000 patients, found that those taking telmisartan had a significantly greater risk for new cancer than did controls. When cancer type was analysed, only lung cancer risk was significantly increased. Hence telmisartan should be confined to those intolerant to ACE inhibitors. (MIMS).

Adverse Reaction:

TELMISTRAN

CNS -

Dizziness 1% ,Insomnia >0.3%, Headache 1% ,Fatigue 1% Anxiety/nervousness ,Depression > 0.3%

GI -

Diarrhea 3% Dyspepsia /heartburn 1% Nausea/vomiting 1% Abdomnal pain 1%

Musculoskeletal-

Arthalgia > 0.3% Pain 3% Myalgia 1%

Respiratory -

Upper Res tract infn 7% Cough 1% Sinusitis 3% Pharyngitis 1% Rhinitis 0.3%
Influnz symptoms 1% Bronchitis 0.3%

Miscellaneous-

Chest pain 1% Rash > 0.3% Tacycardia > 0.3% Urinary tract infn 1%
Peripheral edema 1% Hypertension 1%

Contra-Indications:

Severe hepatic impairment, Biliary obstructive disorders

Pregnancy Lactation

Special precautions-

Hepatic insufficiency , Biliary obstructive , renal impairment

Renaly artery stenosis.

Correct volume depletion before initiating treatment

Monitor serum K levels regularly, especially in elderly and renally impaired patients

Dosages/ Overdosage Etc:

Indication-

Hypertension

Dosage

Adults 40mg once daily Max 80mg /day

Pregnancy and lactation:

Use contraindicated during pregnancy and lactation.

Observe caution if use is needed

Search

Look In

Keyword

Mode

	Starts With		Contains

Quick Links

Home
About Us
FAQs
Site Map
Disclaimer

Free Mobile App

About Us

FAQs

Feedback

Disclaimer: Every effort has been made to ensure that the information provided in this Database is authentic and accurate. Commissions or omissions in the database, if any, are purely inadvertent and the site owner shall not accept any liability whatsoever for any adverse consequences of any nature arising to any individual or third party, as a result of usage of this information.